AI Terminal
Vimian Group AB
Board/Management Information • Sep 23, 2025
8618_rns_2025-09-23_b7e2880c-2e49-4789-83c3-05eb797c36f0.pdf
Board/Management Information
Open in ViewerOpens in native device viewer
Nomination Committee for Vimian's 2026 Annual General Meeting
The Nomination Committee for Vimian Group has been appointed.
Vimian's Nomination Committee for the 2026 Annual General Meeting has been appointed based on the ownership structure as of 31 August 2025.
The Nomination Committee comprises the following members:
Håkan Håkansson, Fidelio Capital
Suzanne Sandler, Handelsbanken Fonder
Caroline Sjösten, Swedbank Robur Fonder
Magnus Welander, Chairman of the Board
Chairman of the Nomination Committee will be appointed at the Nomination Committee's first meeting.
The Annual General Meeting of Vimian Group will be held on 29 April 2026. Shareholders who would like to submit proposals to the Nomination Committee for the 2026 Annual General Meeting can submit such via email to [email protected] no later than 16 February 2026.
For further information, please contact:
Maria Dahllöf Tullberg
Head of IR, Communications & Sustainability [email protected] +46 73 626 88 86
About Vimian
Vimian is a global animal health company covering four essential and rapidly evolving areas: Specialty Pharma, MedTech, Veterinary Services and Diagnostics. At Vimian, we believe that every animal deserves the best available care. We bring pioneering and entrepreneurial businesses together to make the market's most innovative offerings accessible to more animal health professionals and pet owners. Headquartered in Stockholm, Sweden, Vimian reaches over 17,000 veterinary clinics and laboratories, sells to over 80 markets, has 1,200 employees and annual revenues of approximately EUR 375 million. For more information, please visit: www.vimian.com.
Attachments
Nomination Committee for Vimian's 2026 Annual General Meeting